{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:51:49Z","timestamp":1781891509693,"version":"3.54.5"},"reference-count":159,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.retram.2026.103584","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:50:22Z","timestamp":1774885822000},"page":"103584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral CXCR4 inhibition with mavorixafor: Emerging therapeutic applications in WHIM syndrome, chronic neutropenia, oncology, and stem cell mobilization"],"prefix":"10.1016","volume":"74","author":[{"given":"Loi","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-224X","authenticated-orcid":false,"given":"Chi Huu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.retram.2026.103584_bib0001","article-title":"CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease","volume":"48","author":"De Filippo","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"1-3","key":"10.1016\/j.retram.2026.103584_bib0002","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1385\/IR:32:1-3:169","article-title":"Neutrophil homeostasis: a new role for stromal cell-derived factor-1","volume":"32","author":"Link","year":"2005","journal-title":"Immunol Res"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10555-010-9256-x","article-title":"CXCL12 \/CXCR4 \/ CXCR7 chemokine axis and cancer progression","volume":"29","author":"Sun","year":"2010","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"10.1016\/j.retram.2026.103584_bib0004","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.7150\/ijbs.82317","article-title":"CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications","volume":"19","author":"Yang","year":"2023","journal-title":"Int J Biol Sci"},{"issue":"18","key":"10.1016\/j.retram.2026.103584_bib0005","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.3390\/cancers15184555","article-title":"The role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 ligands in molecular cancer processes and clinical aspects of acute myeloid leukemia (AML)","volume":"15","author":"Korbecki","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.retram.2026.103584_bib0006","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3390\/cancers14092314","article-title":"CXCR4\/CXCL12 activities in the tumor microenvironment and implications for tumor immunotherapy","volume":"14","author":"Mezzapelle","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2026.103584_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0008","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1007\/s10875-022-01312-7","article-title":"Disease progression of WHIM syndrome in an international cohort of 66 pediatric and adult patients","volume":"42","author":"Geier","year":"2022","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12719","article-title":"WHIM syndrome: Immunopathogenesis, treatment and cure strategies","volume":"287","author":"McDermott","year":"2019","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0010","article-title":"Waldenstrom macroglobulinemia - a state-of-the-art review: part 1: epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems","volume":"16","author":"Bibas","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0011","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000509286","article-title":"Current and emerging treatments for Waldenstrom macroglobulinemia","volume":"144","author":"Grimont","year":"2021","journal-title":"Acta Haematol"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0012","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1080\/10428194.2021.1881514","article-title":"Clinical application of genomics in Waldenstrom macroglobulinemia","volume":"62","author":"Branagan","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.retram.2026.103584_bib0013","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv Cancer Res"},{"issue":"20","key":"10.1016\/j.retram.2026.103584_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012499","article-title":"Targeting CXCR4 and CD47 receptors: an overview of new and old molecules for a biological personalized anticancer therapy","volume":"23","author":"Leo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3390\/pharmaceutics14081541","article-title":"Recent advances in CXCL12\/CXCR4 antagonists and nano-based drug delivery systems for cancer therapy","volume":"14","author":"Zhao","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0016","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood.2023022658","article-title":"A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome","volume":"144","author":"Badolato","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0017","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/2767-9764.CRC-22-0090","article-title":"Mavorixafor, an orally bioavailable CXCR4 antagonist, increases immune cell infiltration and inflammatory status of tumor microenvironment in patients with melanoma","volume":"2","author":"Andtbacka","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103584_bib0018","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2021-144706","article-title":"Preliminary clinical response data from a phase 1b study of Mavorixafor in combination with ibrutinib in patients with Waldenstr\u00f6m's macroglobulinemia with MYD88 and CXCR4 mutations","volume":"138","author":"Treon","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0019","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10637-020-01058-2","article-title":"A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy","volume":"39","author":"Choueiri","year":"2021","journal-title":"Invest New Drugs"},{"issue":"26","key":"10.1016\/j.retram.2026.103584_bib0020","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1182\/blood.2020007197","article-title":"Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome","volume":"136","author":"Dale","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103584_bib0021","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2022-156216","article-title":"Mavorixafor for patients with chronic neutropenic disorders: results from a phase 1b, open-label, multicenter study","volume":"140","author":"Warren","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103584_bib0022","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood-2023-173549","article-title":"Mavorixafor for patients with chronic neutropenic disorders treated with G-CSF: preliminary response data and G-CSF dose reduction in an ongoing phase 2, open-label, multicenter study support reduction in G-CSF dosing","volume":"142","author":"Warren","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103584_bib0023","series-title":"Evaluating the safety and efficacy of mavorixafor, an oral cxcr4 antagonist, in patients with chronic neutropenic disorders: results from the phase 2 study. Proceeding in 30th European Hematology Association conference","author":"Warren","year":"2025"},{"key":"10.1016\/j.retram.2026.103584_bib0024","series-title":"Proceeding in 30th European Hematology Association conference","article-title":"Mavorixafor, an oral Cxcr4 antagonist, allows for granulocyte-colony stimulating factor dose de-escalation in patients with chronic idiopathic neutropenia and congenital neutropenia","author":"Warren","year":"2025"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0025","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/leu.2011.76","article-title":"Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist","volume":"25","author":"Parameswaran","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0026","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3892\/or.2022.8279","article-title":"Enhanced CXCL12\/CXCR4 signaling increases tumor progression in radiation\u2011resistant pancreatic cancer","volume":"47","author":"Kato","year":"2022","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0027","first-page":"303","article-title":"Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells","volume":"40","author":"Uchida","year":"2018","journal-title":"Oncol Rep"},{"issue":"Supplement_5","key":"10.1016\/j.retram.2026.103584_bib0028","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/annonc\/mdz253.012","article-title":"Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment","volume":"30","author":"McDermott","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0029","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/med.21464","article-title":"Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology","volume":"38","author":"Tsou","year":"2018","journal-title":"Med Res Rev"},{"issue":"6007","key":"10.1016\/j.retram.2026.103584_bib0030","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.1194396","article-title":"Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists","volume":"330","author":"Wu","year":"2010","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0031","doi-asserted-by":"crossref","DOI":"10.4155\/fdd-2022-0007","article-title":"CXCR4 as a novel target in immunology: moving away from typical antagonists","volume":"4","author":"Caspar","year":"2022","journal-title":"Future Drug Discov"},{"key":"10.1016\/j.retram.2026.103584_bib0032","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fendo.2019.00585","article-title":"The role of the CXCL12\/CXCR4\/ACKR3 axis in autoimmune diseases","volume":"10","author":"Garcia-Cuesta","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.retram.2026.103584_bib0033","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.imlet.2016.06.006","article-title":"CXCR4 signaling in health and disease","volume":"177","author":"Pozzobon","year":"2016","journal-title":"Immunol Lett"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0034","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstrom's Macroglobulinema: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0035","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s10875-019-00665-w","article-title":"WHIM syndrome: from pathogenesis towards personalized medicine and cure","volume":"39","author":"Heusinkveld","year":"2019","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0036","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.retram.2026.103584_bib0037","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)-directed survival signalling in Waldenstrom macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0038","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic landscape of CXCR4 mutations in Waldenstr\u00f6m macroglobulinemia","volume":"22","author":"Poulain","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.retram.2026.103584_bib0039","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","article-title":"C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma","volume":"123","author":"Roccaro","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0040","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers13040826","article-title":"Targeting of CXCR4 by the naturally occurring CXCR4 antagonist EPI-X4 in Waldenstrom's Macroglobulinemia","volume":"13","author":"Kaiser","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.retram.2026.103584_bib0041","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic landscape of Waldenstrom Macroglobulinemia and its impact on treatment strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.retram.2026.103584_bib0042","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0043","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41435-022-00181-9","article-title":"Genotype-phenotype correlations in WHIM syndrome: a systematic characterization of CXCR4(WHIM) variants","volume":"23","author":"Zmajkovicova","year":"2022","journal-title":"Genes Immun"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0044","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bcp.2011.11.020","article-title":"The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor","volume":"83","author":"Mosi","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.retram.2026.103584_bib0045","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1128\/AAC.00013-07","article-title":"Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects","volume":"51","author":"Stone","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.retram.2026.103584_bib0046","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-7-71","article-title":"Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry","volume":"7","author":"Beaussant Cohen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0047","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MOH.0b013e32831ac557","article-title":"WHIM syndrome: congenital immune deficiency disease","volume":"16","author":"Kawai","year":"2009","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0048","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/ijms20010003","article-title":"Adaptive immunodeficiency in WHIM syndrome","volume":"20","author":"Majumdar","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0049","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10875-017-0457-8","article-title":"Mechanisms of sustained neutrophilia in patient WHIM-09, cured of WHIM syndrome by chromothripsis","volume":"38","author":"Liu","year":"2018","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood-2011-12-395608","article-title":"WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4","volume":"120","author":"Liu","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0051","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2004-06-2289","article-title":"WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12","volume":"105","author":"Balabanian","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0052","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/blood-2003-10-3532","article-title":"Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome","volume":"104","author":"Gulino","year":"2004","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.retram.2026.103584_bib0053","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2013-09-527226","article-title":"A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor","volume":"123","author":"McDermott","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.retram.2026.103584_bib0054","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2011-07-368084","article-title":"The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome","volume":"118","author":"McDermott","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.retram.2026.103584_bib0055","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1182\/blood-2011-06-360586","article-title":"The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome","volume":"118","author":"Dale","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0056","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/MS9.0000000000003030","article-title":"Mavorixafor, CXCR4 antagonist, a novel treatment for WHIM syndrome, first FDA approval 2024","volume":"87","author":"Waheed","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"11","key":"10.1016\/j.retram.2026.103584_bib0057","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1097\/MS9.0000000000002590","article-title":"Xolremdi (Mavorixafor): a breakthrough in WHIM syndrome treatment - unraveling efficacy and safety in a rare disease frontier","volume":"86","author":"Nadeem","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0058","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s40265-024-02063-y","article-title":"Mavorixafor: first approval","volume":"84","author":"Hoy","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.2024024942","article-title":"Mavorixafor: a new hope for WHIM syndrome","volume":"144","author":"Geier","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMoa1808575","article-title":"Plerixafor for the treatment of WHIM syndrome","volume":"380","author":"McDermott","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.retram.2026.103584_bib0061","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164918","article-title":"A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome","volume":"133","author":"McDermott","year":"2023","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0062","doi-asserted-by":"crossref","first-page":"e872","DOI":"10.1097\/HS9.0000000000000872","article-title":"The European guidelines on diagnosis and management of neutropenia in adults and children: a consensus between the European hematology association and the EuNet-INNOCHRON COST action","volume":"7","author":"Fioredda","year":"2023","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0063","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MOH.0000000000000305","article-title":"An update on the diagnosis and treatment of chronic idiopathic neutropenia","volume":"24","author":"Dale","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0064","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.14887","article-title":"Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history","volume":"179","author":"Donadieu","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2026.103584_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.32","article-title":"Severe congenital neutropenias","volume":"3","author":"Skokowa","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0066","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/hematology.2022000392","article-title":"Genetics of severe congenital neutropenia as a gateway to personalized therapy","volume":"2022","author":"Donadieu","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0067","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2141.2009.07888.x","article-title":"Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia","volume":"147","author":"Xia","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.retram.2026.103584_bib0068","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood-2006-08-019166","article-title":"Neutrophil elastase in cyclic and severe congenital neutropenia","volume":"109","author":"Horwitz","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2012.11.003","article-title":"Epidemiology of congenital neutropenia","volume":"27","author":"Donadieu","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"10.1016\/j.retram.2026.103584_bib0070","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood.V81.10.2496.2496","article-title":"A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia","volume":"81","author":"Dale","year":"1993","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.retram.2026.103584_bib0071","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/bloodadvances.2021005684","article-title":"Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor","volume":"6","author":"Dale","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.retram.2026.103584_bib0072","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1182\/bloodadvances.2023012171","article-title":"Impact of different genetic mutations on granulocyte development and G-CSF responsiveness in congenital neutropenia","volume":"8","author":"Meng","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0073","first-page":"45","article-title":"Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French severe chronic neutropenia study group","volume":"90","author":"Donadieu","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0074","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.22242","article-title":"Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica)","volume":"87","author":"Fioredda","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2010.08216.x","article-title":"Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy","volume":"150","author":"Rosenberg","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0076","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/leu.2009.56","article-title":"The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation","volume":"23","author":"Abraham","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0077","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/bjc.2013.124","article-title":"Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070","volume":"108","author":"O'Boyle","year":"2013","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.retram.2026.103584_bib0078","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.3390\/ijms20194740","article-title":"The CXCR4-CXCL12-axis is of prognostic relevance in DLBCL and its antagonists exert pro-apoptotic effects in vitro","volume":"20","author":"Pansy","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"Suppl","key":"10.1016\/j.retram.2026.103584_bib0079","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/01.HS9.0000847876.35483.fd","article-title":"Mavorixafor disrupts the cross talk between Waldenstr\u00f6m\u2019s macroglobulinemia cells and the bone marrow microenvironment resulting in enhanced sensitivity to B-cell targeted therapies","volume":"6","author":"Monticelli","year":"2022","journal-title":"Hemasphere"},{"issue":"Supplement_7","key":"10.1016\/j.retram.2026.103584_bib0080","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1158\/1538-7445.AM2023-5866","article-title":"Mavorixafor enhances apoptosis of tumor cells treated with ibrutinib or venetoclax in diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia","volume":"83","author":"Kruitwagen","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.retram.2026.103584_bib0081","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12885-016-2340-z","article-title":"Enhancement of the CXCL12\/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists","volume":"16","author":"Morimoto","year":"2016","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0082","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hemonc.2019.05.002","article-title":"Updates in prognostication and treatment of Waldenstr\u00f6m's macroglobulinemia","volume":"12","author":"Advani","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"10","key":"10.1016\/j.retram.2026.103584_bib0083","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474086.2019.1649132","article-title":"CXCR4 mutations affect presentation and outcomes in patients with Waldenstrom macroglobulinemia: a systematic review","volume":"12","author":"Castillo","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"18","key":"10.1016\/j.retram.2026.103584_bib0084","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0085","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1016\/j.clml.2019.03.009","article-title":"Characteristics of Waldenstrom Macroglobulinemia in Korean patients according to mutational status of MYD88 and CXCR4: analysis using ultra-deep sequencing","volume":"19","author":"Shin","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.retram.2026.103584_bib0086","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstrom macroglobulinemia or IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.retram.2026.103584_bib0087","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0088","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/2040620711410096","article-title":"The bone marrow microenvironment in waldenstrom macroglobulinemia","volume":"2","author":"Ghobrial","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.retram.2026.103584_bib0089","article-title":"Promising phase 1b results: Mavorixafor + Ibrutinib in the treatment of Waldenstr\u00f6m\u2019s","author":"Release","year":"2022","journal-title":"Macroglobulinemia"},{"issue":"15","key":"10.1016\/j.retram.2026.103584_bib0090","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103584_bib0091","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.omto.2020.06.009","article-title":"CXCR4 antagonist AMD3100 reverses the resistance to tamoxifen in breast cancer via inhibiting AKT phosphorylation","volume":"18","author":"Zhou","year":"2020","journal-title":"Mol Ther Oncol"},{"issue":"7","key":"10.1016\/j.retram.2026.103584_bib0092","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.18632\/oncotarget.3217","article-title":"CXCR4 over-expression and survival in cancer: a system review and meta-analysis","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.retram.2026.103584_bib0093","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/JTO.0b013e3182199a99","article-title":"CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer","volume":"6","author":"Otsuka","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.retram.2026.103584_bib0094","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1477-7819-10-212","article-title":"High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma","volume":"10","author":"Wang","year":"2012","journal-title":"World J Surg Oncol"},{"issue":"11","key":"10.1016\/j.retram.2026.103584_bib0095","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.oraloncology.2011.07.021","article-title":"Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma","volume":"47","author":"Clatot","year":"2011","journal-title":"Oral Oncol"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0096","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071864","article-title":"Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer","volume":"8","author":"He","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0097","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1245\/s10434-010-0970-y","article-title":"Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy","volume":"17","author":"Saigusa","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.retram.2026.103584_bib0098","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1200\/JCO.2005.07.078","article-title":"Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival","volume":"23","author":"Kim","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0099","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ijc.28689","article-title":"A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients","volume":"135","author":"D'Alterio","year":"2014","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jss.2008.09.020","article-title":"High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome","volume":"159","author":"Chu","year":"2010","journal-title":"J Surg Res"},{"issue":"14","key":"10.1016\/j.retram.2026.103584_bib0101","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.ejca.2009.06.026","article-title":"CXCL12\/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival","volume":"45","author":"Mirisola","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0102","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jss.2007.03.015","article-title":"Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence","volume":"141","author":"Holm","year":"2007","journal-title":"J Surg Res"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0103","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cncr.22510","article-title":"Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype","volume":"109","author":"Konoplev","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0104","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/PAI.0b013e3182606f4d","article-title":"The prognostic value of CXCR4 in acute myeloid leukemia","volume":"21","author":"Ahn","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0105","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl053","article-title":"Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer","volume":"17","author":"Andre","year":"2006","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.retram.2026.103584_bib0106","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/bjc.2012.49","article-title":"The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer","volume":"106","author":"Popple","year":"2012","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.retram.2026.103584_bib0107","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/diagnostics14111195","article-title":"CXCR4 expression as a prognostic biomarker in soft tissue sarcomas","volume":"14","author":"Virgili","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0108","first-page":"741","article-title":"Bioinformatic analyses reveal the key pathways and genes in the CXCR4 mediated mesenchymal subtype of glioblastoma","volume":"18","author":"Yi","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.retram.2026.103584_bib0109","doi-asserted-by":"crossref","DOI":"10.1177\/1744806920919568","article-title":"Chemokine receptor CXCR4 activates the RhoA\/ROCK2 pathway in spinal neurons that induces bone cancer pain","volume":"16","author":"Xu","year":"2020","journal-title":"Mol Pain"},{"issue":"219","key":"10.1016\/j.retram.2026.103584_bib0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007563","article-title":"Therapeutic inflammatory monocyte modulation using immune-modifying microparticles","volume":"6","author":"Getts","year":"2014","journal-title":"Sci Transl Med"},{"issue":"46","key":"10.1016\/j.retram.2026.103584_bib0111","doi-asserted-by":"crossref","first-page":"39115","DOI":"10.1074\/jbc.M112.409581","article-title":"CXCL12\/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase- and Akt kinase-mediated activation of nuclear factor kappaB: implications for bidirectional tumor-stromal interactions","volume":"287","author":"Singh","year":"2012","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.retram.2026.103584_bib0112","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.4446","article-title":"CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival","volume":"235","author":"Moreno","year":"2015","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0113","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.breast.2005.08.034","article-title":"Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer","volume":"15","author":"Su","year":"2006","journal-title":"Breast"},{"issue":"23","key":"10.1016\/j.retram.2026.103584_bib0114","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.1158\/1078-0432.CCR-05-0537","article-title":"Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells","volume":"11","author":"Su","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0115","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1053\/j.gastro.2005.06.056","article-title":"CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer","volume":"129","author":"Saur","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.retram.2026.103584_bib0116","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ijc.29864","article-title":"CXCL12\/CXCR4 activation by cancer-associated fibroblasts promotes integrin beta1 clustering and invasiveness in gastric cancer","volume":"138","author":"Izumi","year":"2016","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.retram.2026.103584_bib0117","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/cam.3.3.8260","article-title":"Functional diversity of SDF-1 splicing variants","volume":"3","author":"Janowski","year":"2009","journal-title":"Cell Adh Migr"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0118","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41598-019-38643-2","article-title":"CXCR4 signaling regulates metastatic onset by controlling neutrophil motility and response to malignant cells","volume":"9","author":"Tulotta","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0119","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1158\/1078-0432.CCR-10-2636","article-title":"CXCL12 (SDF1alpha)-CXCR4\/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?","volume":"17","author":"Duda","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.retram.2026.103584_bib0120","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0121","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.canlet.2014.08.012","article-title":"SDF-1\/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt\/beta-catenin signaling pathway","volume":"354","author":"Hu","year":"2014","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0122","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s11064-016-1831-2","article-title":"CXCL12\/CXCR4 axis improves migration of neuroblasts along corpus callosum by stimulating MMP-2 secretion after traumatic brain injury in rats","volume":"41","author":"Mao","year":"2016","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0123","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/path.1876","article-title":"Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes","volume":"208","author":"Parmo-Cabanas","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.retram.2026.103584_bib0124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.gene.2017.10.015","article-title":"The role of CXCL12 in tumor microenvironment","volume":"641","author":"Meng","year":"2018","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/07357907.2017.1422512","article-title":"Knockdown of CXCR4 inhibits CXCL12-induced angiogenesis in HUVECs through downregulation of the MAPK\/ERK and PI3K\/AKT and the Wnt\/beta-catenin pathways","volume":"36","author":"Song","year":"2018","journal-title":"Cancer Invest"},{"issue":"32","key":"10.1016\/j.retram.2026.103584_bib0126","doi-asserted-by":"crossref","first-page":"14484","DOI":"10.1073\/pnas.1008256107","article-title":"CXCR4\/YY1 inhibition impairs VEGF network and angiogenesis during malignancy","volume":"107","author":"de Nigris","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.retram.2026.103584_bib0127","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/labinvest.3700482","article-title":"Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion","volume":"86","author":"Zagzag","year":"2006","journal-title":"Lab Invest"},{"issue":"3","key":"10.1016\/j.retram.2026.103584_bib0128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.2908","article-title":"The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K\/AKT signalling","volume":"224","author":"Ping","year":"2011","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.retram.2026.103584_bib0129","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2007.05.182","article-title":"CXCR4\/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway","volume":"359","author":"Liang","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.retram.2026.103584_bib0130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0131","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/carcin\/bgn228","article-title":"Stromal cell-derived factor-1alpha (SDF-1alpha\/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1\/2-NF-kappaB\/interleukin-6 pathway","volume":"30","author":"Chu","year":"2009","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0132","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1158\/0008-5472.CAN-06-2971","article-title":"A glycolytic mechanism regulating an angiogenic switch in prostate cancer","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0133","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","article-title":"Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy","volume":"16","author":"Alghamri","year":"2022","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0134","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13046-018-1014-x","article-title":"CXCL12\/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p","volume":"38","author":"Yu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.retram.2026.103584_bib0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2019.10.032","article-title":"Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model","volume":"469","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"issue":"17","key":"10.1016\/j.retram.2026.103584_bib0136","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.2021012953","article-title":"Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstrom macroglobulinemia","volume":"138","author":"Treon","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2026.103584_bib0137","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/1078-0432.CCR-19-0647","article-title":"A phase Ib\/II trial of the first-in-class anti-CXCR4 antibody Ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma","volume":"26","author":"Ghobrial","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.retram.2026.103584_bib0138","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/JLB.2BT1018-715RR","article-title":"At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer","volume":"109","author":"Luker","year":"2021","journal-title":"J Leukoc Biol"},{"issue":"11","key":"10.1016\/j.retram.2026.103584_bib0139","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/17425247.2025.2556320","article-title":"From stem cell transplantation to stem cell-based drug delivery systems targeting hematological malignancies: recent advances and clinical considerations","volume":"22","author":"Zhang","year":"2025","journal-title":"Expert Opin Drug Deliv"},{"issue":"19","key":"10.1016\/j.retram.2026.103584_bib0140","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.3390\/cancers17193237","article-title":"The evolving role of hematopoietic stem cell transplantation in Philadelphia-like acute lymphoblastic leukemia: from high-risk standard to precision strategies","volume":"17","author":"Molica","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2026.103584_bib0141","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231174304","article-title":"Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide","volume":"14","author":"Crees","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"18","key":"10.1016\/j.retram.2026.103584_bib0142","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1182\/bloodadvances.2023010407","article-title":"Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor","volume":"7","author":"Crees","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0143","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s42003-021-02070-9","article-title":"Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization","volume":"4","author":"Jorgensen","year":"2021","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.retram.2026.103584_bib0144","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-016-1107-2","article-title":"Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial","volume":"15","author":"Karpova","year":"2017","journal-title":"J Transl Med"},{"issue":"23","key":"10.1016\/j.retram.2026.103584_bib0145","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.retram.2026.103584_bib0146","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.retram.2026.103584_bib0147","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1634\/stemcells.2007-0161","article-title":"Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003","volume":"25","author":"Abraham","year":"2007","journal-title":"Stem Cells"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0148","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/biom14081003","article-title":"Development of VLA4 and CXCR4 antagonists for the mobilization of hematopoietic stem and progenitor cells","volume":"14","author":"Ruminski","year":"2024","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0149","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/bloodadvances.2023011653","article-title":"Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization","volume":"8","author":"Cancilla","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.retram.2026.103584_bib0150","first-page":"497","article-title":"Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications","volume":"21","author":"Azevedo-Pereira","year":"2008","journal-title":"Acta Med Port"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0151","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1086\/597097","article-title":"Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1","volume":"48","author":"Moyle","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0152","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1021\/jm100073m","article-title":"Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication","volume":"53","author":"Skerlj","year":"2010","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.retram.2026.103584_bib0153","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/aid.2018.0256","article-title":"Antiretroviral activity of AMD11070 (an orally administered CXCR4 entry inhibitor): results of NIH\/NIAID AIDS clinical trials group protocol A5210","volume":"35","author":"Johnson","year":"2019","journal-title":"AIDS Res Hum Retrovirus"},{"issue":"11","key":"10.1016\/j.retram.2026.103584_bib0154","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.27685","article-title":"Dysregulated expression of CXCR4\/CXCL12 in subsets of patients with systemic lupus erythematosus","volume":"62","author":"Wang","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.retram.2026.103584_bib0155","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.3892\/mmr.2016.4965","article-title":"CXCR4 antagonist AMD3100 ameliorates thyroid damage in autoimmune thyroiditis in NOD.H\u20112h(4) mice","volume":"13","author":"Liu","year":"2016","journal-title":"Mol Med Rep"},{"issue":"7","key":"10.1016\/j.retram.2026.103584_bib0156","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.4049\/jimmunol.0801920","article-title":"CXCR4\/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus","volume":"182","author":"Wang","year":"2009","journal-title":"J Immunol"},{"issue":"17","key":"10.1016\/j.retram.2026.103584_bib0157","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.retram.2026.103584_bib0158","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.18632\/oncotarget.2407","article-title":"Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition","volume":"5","author":"Sison","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.retram.2026.103584_bib0159","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1111\/jcmm.14269","article-title":"SDF-1\/CXCR4 signalling is involved in blood vessel growth and remodelling by intussusception","volume":"23","author":"Dimova","year":"2019","journal-title":"J Cell Mol Med"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:56:25Z","timestamp":1781888185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":159,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2452318626000206"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103584","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral CXCR4 inhibition with mavorixafor: Emerging therapeutic applications in WHIM syndrome, chronic neutropenia, oncology, and stem cell mobilization","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103584"}}